The RADAAR consortium is led by the International Vaccine Institute (IVI). IVI, based in Seoul, Republic of Korea, develops and introduces new and improved vaccines to protect the world’s poorest people, especially children, in developing countries. IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization (WHO). IVI conducts research in more than 30 countries throughout Asia, Africa and Latin America on epidemiological and disease surveillance, and clinical studies of vaccines against enteric and diarrhoeal infections, Japanese encephalitis, MERS-CoV, and dengue fever, and develops new and improved vaccines.  IVI is the lead grantee for the RADAAR consortium. The three RADAAR consortium partners are:

The Public Health Surveillance Group (PHSG) is a global health consulting group based in the United States. PHSG provides services and support to initiatives in public health surveillance, global health security, research, and monitoring & evaluation. PHSG strives to improve health systems and generate high-quality data to equip decision-makers with the information necessary to reduce morbidity and mortality. PHSG collaborates with leading public health organisations and local governments in over 20 countries in Africa and Asia to enhance vertical and integrated surveillance strategies and systems. PHSG, led by Dr. William MacWright, are also part of the consortium for the IVI-led CAPTURA project, providing support for in-country activities, and expertise in the development of protocols, training modules and monitoring. (see https://captura.ivi.int/), also supported by The Fleming Fund (https://www.flemingfund.org/grants/1-4-collection-of-historical-amr-data-sea/).

The WHONET microbiology database software is already actively used in most CAPTURA countries, capturing and standardising data from diverse laboratory information systems into a common platform, facilitating integrated management, analysis, and interpretation of microbiological findings. John Stelling and the rest of the WHONET development team at Brigham & Women’s Hospital will be supporting data collection and collation from sites that use WHONET and support the in-country capacity building.

Prof. David Aanensen and the team from the Big Data Institute, University of Oxford have developed global methods for epidemiological data linkage (https://microreact.org) to enable the analyses and visualisation of very large datasets. Their expertise will guide the collection and analysis of datasets (including genomic data), interpretation, visualisation, and delivery tools.

The Fleming Fund is a £265 million UK aid investment to tackle antimicrobial resistance in low- and middle-income countries around the world. The programme is managed by the UK Department of Health and Social Care, in partnership with Mott MacDonald, the Fleming Fund Grant Management Agent.

THE FLEMING FUND REGIONAL GRANTS:

IVI PROJECTS